Daiichi Sankyo looking to sell OTC drug unit for about $900m

Japan’s Daiichi Sankyo Co is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

Reuters reported earlier this year that Japan’s No. 4 drugmaker had hired JPMorgan to advise on the potential sale of the unit, Daiichi Sankyo Healthcare.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter